
Parsaclisib HCl
CAS No. 1995889-48-9
Parsaclisib HCl ( INCB50465 HCl | INCB-50465 | INCB 50465 | INCB050465 HCl | INCB-050465 | INCB 050465 )
产品货号. M23900 CAS No. 1995889-48-9
Parsaclisib HCl 是一种具有抗肿瘤活性的选择性 PI3Kδ 抑制剂。 Parsaclisib 表现出有效的活性,IC50 值范围为 0.2 至 2 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥2624 | 有现货 |
![]() ![]() |
50MG | ¥13041 | 有现货 |
![]() ![]() |
100MG | ¥20817 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Parsaclisib HCl
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Parsaclisib HCl 是一种具有抗肿瘤活性的选择性 PI3Kδ 抑制剂。 Parsaclisib 表现出有效的活性,IC50 值范围为 0.2 至 2 nM。
-
产品描述Parsaclisib HCl is a selectve PI3Kδ inhibitor with antitumor activity. Parsaclisib demonstrates potent activity with IC50 values ranging from 0.2 to 2 nM.
-
体外实验Parsaclisib (0.1-3000 nM; 4 d) inhibits proliferation of MCL and DLBCL cell lines.Parsaclisib (0.1-1000 nM; 2 h) inhibits anti-IgM-induced pAKT (Ser473) in the Ramos Burkitt’s lymphoma cell line, with an IC50 of 1 nM.Parsaclisib inhibits the proliferation of human, dog, rat, and mouse primary B cells after activation of these receptors, with IC50s ranging from 0.2 to 1.7 nM. Cell Proliferation AssayCell Line:Jeko-1, Mino, JVM2, Rec-1, Pfeiffer, SU-DHL-5, SU-DHL-6, WSU-NHL, SU-DHL-4, SU-DHL-8, and WILL-2 cells Concentration:0.1-3000 nM Incubation Time:4 days Result:Resulted in a maximal inhibition of 70-90%, with IC50s of ≤10 nM in the four MCL cell lines.Pfeiffer, SU-DHL-5, SU-DHL-6, and WSU-NHL were highly sensitive, with IC50s from 2 to 8 nM.
-
体内实验Parsaclisib (10 mg/kg; oral gavage twice daily for 7-19 days) inhibits tumor growth in the BALB/c mice bearing the A20 murine lymphoma cells.Parsaclisib (0.1-10 mg/kg; p.o. twice daily) slows Pfeiffer xenograft tumor growth in a dose-dependent manner. And Parsaclisib was well tolerated.Parsaclisib (0.5-1 mg/kg; a single p.o.) inhibits pAKT (Ser473) in Pfeiffer subcutaneous mouse xenograft models. Animal Model:Female BALB/c mice (5-9 weeks) were inoculated with A20 cells Dosage:10 mg/kg Administration:Oral gavage twice daily for 7-19 days Result:Resulted in significant tumor growth inhibition (TGI).Reduced the percentage of Tregs (CD4+CD25+FOXP3+) in tumors and spleens.Increased the ratio of CD4+ and CD8+ T cells to Tregs in spleens and tumors.Decreased the number of CD4+CD44 high and CD8+CD44 high T cells in both spleens and tumors.
-
同义词INCB50465 HCl | INCB-50465 | INCB 50465 | INCB050465 HCl | INCB-050465 | INCB 050465
-
通路PI3K/Akt/mTOR signaling
-
靶点PI3K
-
受体PI3Kδ
-
研究领域——
-
适应症——
化学信息
-
CAS Number1995889-48-9
-
分子量469.34
-
分子式C20H23Cl2FN6O2
-
纯度>98% (HPLC)
-
溶解度DMSO:90 mg/mL(191.76 mM);Water:Insoluble
-
SMILESO=C1NC[C@@H](C2=C(F)C(Cl)=CC([C@@H](N3N=C(C)C4=C(N)N=CN=C43)C)=C2OCC)C1.[H]Cl
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Shin N, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15)
产品手册




关联产品
-
Tectorigenin
鸢尾皂甙元是一种 O-甲基化异黄酮。鸢尾皂甙元促进成骨细胞分化和体内骨愈合。
-
PI-3065
PI3K p110δ 的有效抑制剂,IC50/Ki 值分别为 5/1.5 nM。
-
NVP-BKM120
NVP-BKM120(BKM-120,Buparlisib)是一种有效的、选择性的、口服生物可利用的 I 类 PI3K 亚型抑制剂。